在炎症性肠道疾病中,腺素介导的免疫反应
Marta Vuerich1, Du Hanh Nguyen2,3, Davide Ferrari4
1Biomedical Research, Novartis Pharma AG, Basel, Switzerland.
Frontiers in cell and developmental biology
|August 27, 2024
概括
细胞外腺由ATP生成,由CD39和CD73等酶生成,有助于阻止炎症. 向腺受体为炎症性肠病 (IBD) 提供了潜在的治疗方法.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 细胞外ATP信号通路与炎症状况有关.
- 腺素是通过核酸酶 (例如,ENTPD1/CD39,CD73) 进行ATP水解的产物,对于解决炎症和促进免疫耐受性至关重要.
- 免疫细胞上的腺素受体调节先天性和适应性免疫.
研究的目的:
- 审查最近关于腺介导免疫反应的发现.
- 专注于腺受体在炎症性肠病 (IBD) 中的作用,包括克罗恩病和性结肠炎.
主要方法:
- 对炎症中腺信号传递研究的文献综述.
- 对IBD患者和动物模型研究的分析.
- 讨论当前对免疫细胞中腺受体调节的理解.
主要成果:
- 像CD39和CD73这样的ectonucleotidases将ATP降解为腺,它具有免疫抑制作用.
- 腺素受体在调节IBD等慢性炎症性疾病方面发挥着重要作用.
- 改变的肠道微生物群和免疫系统相互作用与IBD病原发生有关.
结论:
- 针对细胞外ATP和腺信号通路,为炎症条件提供了潜在的治疗策略.
- 了解腺受体功能是开发IBD新型治疗方法的关键.
- 对腺介导免疫反应的进一步研究可以推进IBD治疗.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120
Inflammatory Bowel Disease IV: Pharmacological Management
123
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
123
Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Cell-mediated Immune Responses
67.9K
Overview
67.9K


